MarketPulse

pipeline drugs

2 articles
The Motley FoolThe Motley Fool··Eric Volkman

JPMorgan Lifts Edgewise Therapeutics on Pipeline Optimism, Stock Surges

JPMorgan raises Edgewise Therapeutics price target to $45, citing positive long-term clinical data for EDG-7500 and sevasemten. Stock rises 2.18%.
AMJBJPMJPMpCJPMpDJPMpJ+5clinical databiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Checkpoint Inhibitor Market Analysis: 50+ Players Drive Immuno-Oncology Innovation Through 2026

Over 50 companies compete in the checkpoint inhibitor market with 60+ drug candidates in development. Major consolidation and innovation drive immuno-oncology growth through 2026.
BMYCELGrKYKOYRNAZclinical trialscompetitive landscape